Weitai Medical-B (02235) Fa Yingxi expects net profit to be no less than 36 million yuan in the medium term, turning a year-on-year loss into a profit

According to the Zhitong Finance App, Weitai Medical-B (02235) announced that the Group's revenue for the six months ended June 30, 2026 (reporting period) will be no less than RMB 400 million, compared with RMB 246 million for the six months ended June 30, 2025, an increase of no less than 63% over the previous year. It is estimated that the Group's net profit attributable to owners of the parent company during the reporting period will not be less than RMB 36 million, which will turn a loss into a profit compared to RMB 2 million for the six months ended June 30, 2025.

The expected increase mainly benefits from the continued strong growth in revenue from sales of glucose monitoring systems, one of the Group's core products, and continued steady development of products such as adhesive insulin pump systems and blood sugar monitoring systems; continuous improvement in revenue contribution of glucose monitoring systems and improvement in production scale efficiency, driving a significant increase in overall gross margin compared to the same period last year; and significant improvements in operating efficiency, continuous optimization of marketing activities, and a continuous decline in the Group's sales expenses to revenue ratio.